Refresher Course: Hybrid, Molecular and Translational Imaging
RC 806 - ALPHA, BETA, GAMMA: radioligands in action, transforming cancer imaging and therapy
Lectures
1
Chairperson's introduction
05:00Désirée Deandreis, Villejuif / FR
2
Alpha-emitting radionuclide therapy: the next frontier in targeted cancer treatment
15:00Mike Sathekge, Pretoria / ZA
3
Beta-emitting and Auger electron radiopharmaceuticals: impact and opportunities for targeted imaging and therapy
15:00Karolien Goffin, Leuven / BE
4
Gamma emitting imaging: status, success, and future potential in theranostics including dosimetry
15:00Andrei Iagaru, Stanford / US
5
Panel discussion: How and who should we treat
10:00Panel discussion: How and who should we treat
Theranostics is rapidly growing. Alpha-emitting radionuclides increase therapeutic efficacy. Therapeutic radionuclides that decay by emitting β-, such as Lutetium-177, are well established in clinical practice. Radionuclides emitting internal conversion and Auger electrons, e.g. Terbium-161, are approaching translation. Imaging with gamma-emitting radiopharmaceuticals enhance treatment efficacy by personalising radiation doses to individual patients, allowing to maximise tumouricidal therapeutic effects while minimising toxicity to healthy organs. The session outlines the fundamental principles, procedures, and methodologies in imaging, dosimetry and therapy.
5 min
Chairperson's introduction
Désirée Deandreis, Villejuif / France
15 min
Alpha-emitting radionuclide therapy: the next frontier in targeted cancer treatment
Mike Sathekge, Pretoria / South Africa
15 min
Beta-emitting and Auger electron radiopharmaceuticals: impact and opportunities for targeted imaging and therapy
Karolien Goffin, Leuven / Belgium
15 min
Gamma emitting imaging: status, success, and future potential in theranostics including dosimetry
Andrei Iagaru, Stanford / United States
10 min
Panel discussion: How and who should we treat